Pharma Pulse 4/21/25: Using AI to Predict Launch Success, A Pharmacist’s Guide to Blockbuster Patent Expirations: 2025 and Beyond

April 21, 2025

A feature published by Pharmaceutical Executive authored by Anirudh Singh Rathore, Senior Principal of Commercial Solutions, IQVIA and Anirudh Singh Rathore, Principal of Consulting, IQVIA, examines how artificial intelligence is becoming essential in today’s increasingly complex pharmaceutical launch landscape—marked by rising costs for specialty drugs, shorter asset lifecycles, and crowded markets.

A Pharmacist’s Guide to Blockbuster Patent Expirations: 2025 and Beyond

In 2025, the US pharmaceutical market will see major shifts as multiple blockbuster drugs lose exclusivity—ushering in generics and biosimilars, reshaping payer dynamics, and expanding pharmacists' roles in managing substitutions, patient education, and regulatory compliance amid Medicare pricing reforms.

Leading the Technology and Innovation Front Through Rare Disease Research

In this video interview published by Applied Clinical Trials, Derek Ansel, vice president, therapeutic strategy lead, rare disease, Worldwide Clinical Trials, discusses how artificial intelligence can aid in bringing therapies to rare disease patients faster.

Eli Lilly is overtaking Novo Nordisk in the diabetes, obesity market: BMO analysts

BMO Capital Markets has downgraded Novo Nordisk as Eli Lilly pulls ahead in the obesity and diabetes market driven by superior clinical data, stronger product performance, and a more promising pipeline, solidifying Lilly’s lead in the cardiometabolic space.

Stem cells to treat Parkinson's? 2 small studies hint at success

Two small studies show that stem cell transplants can safely produce dopamine and ease symptoms in Parkinson’s patients, marking a major step toward a potentially transformative treatment now headed for Phase III trials.

Have news you want us to share in Pharma Pulse? Reach out to Associate Editor Don Tracy. He can be reached at dtracy@mjhlifesciences.com